WO2024255748A1 - ACIDE NUCLÉIQUE CIBLANT L'HYDROXYSTÉROÏDE 17-β DÉSHYDROGÉNASE 13 ET SON UTILISATION - Google Patents

ACIDE NUCLÉIQUE CIBLANT L'HYDROXYSTÉROÏDE 17-β DÉSHYDROGÉNASE 13 ET SON UTILISATION Download PDF

Info

Publication number
WO2024255748A1
WO2024255748A1 PCT/CN2024/098565 CN2024098565W WO2024255748A1 WO 2024255748 A1 WO2024255748 A1 WO 2024255748A1 CN 2024098565 W CN2024098565 W CN 2024098565W WO 2024255748 A1 WO2024255748 A1 WO 2024255748A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotides
seq
differs
sequence
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2024/098565
Other languages
English (en)
Chinese (zh)
Inventor
蒋伟文
郁东
兰涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synerk Pharmatech Suzhou Ltd
Original Assignee
Synerk Pharmatech Suzhou Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synerk Pharmatech Suzhou Ltd filed Critical Synerk Pharmatech Suzhou Ltd
Publication of WO2024255748A1 publication Critical patent/WO2024255748A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01062—17Beta-estradiol 17-dehydrogenase (1.1.1.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

  • the present invention relates to the field of biotechnology, in particular to a nucleic acid targeting 17- ⁇ -hydroxysteroid dehydrogenase 13 and a use thereof.
  • HSD17B13 17- ⁇ -Hydroxysteroid 17-beta dehydrogenase 13
  • HSD17B13 is an enzyme expressed by the HSD17B13 (also known as FLDP, HMFN0376, NIIL497, SCDR9, SDR16C3) gene.
  • HSD17B13 belongs to the HSD17 protein family, which has 15 enzymes that mainly regulate fatty acid metabolism, cholesterol synthesis, bile synthesis and sex hormone activation.
  • HSD17B13 is mainly expressed specifically in hepatocytes and is confined to the surface of lipid droplets (MacParland, SA et al., Nat. Commun. 2018, 9: 4383).
  • HSD17B13 In patients with nonalcoholic fatty liver disease (NAFLD), the expression of HSD17B13 is significantly increased (Su W et al., Proc. Natl. Acad. Sci. USA 2014, 111: 11437–42.). In GWAS studies, multiple HSD17B13 gene variants were also found to be associated with NAFLD (Anstee QM et al., J. Hepatol. 2020, 73: 505–515), and a HSD17B13 loss-of-function variant (rs72613567:TA) can reduce the risk of NAFLD (Abul-Husn NS et al., N. Engl. J. Med. 2018, 378: 1096–1106).
  • HSD17B13 In animal models, excessive expression of HSD17B13 is associated with NAFLD.
  • the expression of HSD17B13 will significantly increase the number and size of lipid droplets (Su W et al., Proc. Natl. Acad. Sci. USA 2014, 111: 11437–42.).
  • NAFLD nonalcholic steatohepatitis
  • Targeting HSD17B13 may provide a potential means of treating NAFLD.
  • RNA interference refers to the highly conserved phenomenon in the evolutionary process, which is induced by double-stranded small interfering RNA (siRNA) to efficiently and specifically degrade homologous mRNA.
  • siRNA small interfering RNA
  • RNAi drugs also have the advantage of having a longer duration of efficacy than antibodies. Therefore, it is of great significance to study and develop siRNA targeting HSD17B13.
  • the purpose of the present invention is to overcome the problems existing in the prior art and provide a new nucleic acid targeting HSD17B13 and its use.
  • the first aspect of the present invention provides a nucleic acid, which includes a sense chain and an antisense chain, wherein the sense chain contains a sequence having more than 80% sequence identity with the sequence shown in any one of SEQ ID NOs: 1 to 80, and the antisense chain contains a sequence having more than 80% sequence identity with the sequence shown in any one of SEQ ID NOs: 81 to 160.
  • a second aspect of the present invention provides a targeted drug delivery system, which comprises a targeting group, a linking group, and the nucleic acid as described above connected to the targeting group via the linking group.
  • the third aspect of the present invention provides a pharmaceutical composition, which contains the nucleic acid or targeted drug delivery system as described above and a pharmaceutically acceptable carrier.
  • the fourth aspect of the present invention provides a method for inhibiting the expression of 17- ⁇ -hydroxysteroid dehydrogenase 13 gene in a cell, the method comprising: contacting the cell with the nucleic acid, targeted drug delivery system or pharmaceutical composition as described above to inhibit the 17- ⁇ -hydroxysteroid dehydrogenase in the cell. Expression of 13 genes.
  • the fifth aspect of the present invention provides the use of the nucleic acid, targeted drug delivery system or pharmaceutical composition as described above in any of the following aspects: 1) treating and/or preventing diseases associated with 17- ⁇ -hydroxysteroid dehydrogenase 13; 2) preparing drugs for treating and/or preventing diseases associated with 17- ⁇ -hydroxysteroid dehydrogenase 13.
  • the nucleic acid of the present invention can effectively reduce the level of HSD17B13, and can effectively prevent or treat related diseases, such as non-alcoholic fatty liver disease.
  • the technical scheme of "A, and/or, B, and/or, C, and/or, D” includes any one of A, B, C, and D (that is, the technical schemes that are all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four items of A, B, C, and D (that is, the technical schemes that are all connected by "logical AND").
  • the present invention relates to concentration values, and its meaning includes fluctuations within a certain range. For example, it can fluctuate within the corresponding accuracy range. For example, 2% can allow fluctuations within the range of ⁇ 0.1%. For values that are large or do not require too fine control, its meaning is also allowed to include greater fluctuations. For example, 100mM can allow fluctuations within the range of ⁇ 1%, ⁇ 2%, ⁇ 5%, etc. Involving molecular weight, its meaning is allowed to include fluctuations of ⁇ 10%.
  • the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
  • nucleic acid refers to a composition containing RNA or RNA-like (e.g., chemically modified RNA) oligonucleotide molecules, which can degrade or inhibit (e.g., degrade or inhibit under appropriate conditions) the translation of messenger RNA (mRNA) transcripts of target mRNA in a sequence-specific manner.
  • the nucleic acid can act through an RNA interference mechanism (i.e., inducing RNA interference through interaction with the RNA interference pathway mechanism of mammalian cells (RNA-induced silencing complex or RISC)), or through any alternative mechanism or approach.
  • RNA interference mechanism i.e., inducing RNA interference through interaction with the RNA interference pathway mechanism of mammalian cells (RNA-induced silencing complex or RISC)
  • nucleic acids disclosed herein including sense and antisense strands includes, but is not limited to, short (or small) interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), short hairpin RNA (shRNA) and dicer substrates.
  • siRNA short (or small) interfering RNA
  • dsRNA double-stranded RNA
  • miRNA microRNA
  • shRNA short hairpin RNA
  • the terms “silencing”, “reducing”, “inhibiting”, “downregulating” or “knockdown” when referring to the expression of a given gene mean that the expression of the gene is reduced when the cell, cell population, tissue, organ or subject is treated with a nucleic acid described herein, as measured by the level of RNA transcribed from the gene or the level of polypeptide, protein or protein subunit translated from mRNA in a cell, cell population, tissue, organ or subject in which the gene is transcribed, compared to a second cell, cell population, tissue, organ or subject not so treated.
  • "fully complementary” means that in a hybridization pair of nucleobase or nucleotide sequence molecules, all (100%) bases in the contiguous sequence of the first oligonucleotide hybridize with the same number of bases in the contiguous sequence of the second oligonucleotide.
  • the contiguous sequence may include all or part of the first nucleotide sequence or the second nucleotide sequence.
  • substantially complementary means that in a hybridization pair of nucleobase or nucleotide sequence molecules, at least 70% but not all of the bases in the contiguous sequence of the first oligonucleotide hybridize with the same number of bases in the contiguous sequence of the second oligonucleotide.
  • the contiguous sequence may include all or part of the first nucleotide sequence or the second nucleotide sequence.
  • substantially complementary means that in a hybridization pair of nucleobase or nucleotide sequence molecules, at least 85% but not all of the bases in the contiguous sequence of the first oligonucleotide hybridize with the same number of bases in the contiguous sequence of the second oligonucleotide.
  • the contiguous sequence may include the first nucleotide sequence or all or part of a second nucleotide sequence.
  • "at least partially complementary” means that the first oligonucleotide and the second oligonucleotide are partially complementary, substantially complementary or completely complementary in a hybridization pair of nucleobase or nucleotide sequence molecules.
  • the term "treatment” means a method or step taken to provide relief or reduction in the number, severity and/or frequency of one or more disease symptoms in a subject.
  • the treatment may include prevention, management, prophylactic treatment, and/or inhibition or reduction of the number, severity and/or frequency of one or more disease symptoms in a subject.
  • connection means that two compounds or molecules are joined by a covalent bond. Unless otherwise specified, as used herein, the term “connection” may refer to a connection between a first compound and a second compound with or without any intermediate atoms or atomic groups.
  • the present invention provides a (modified or unmodified) nucleic acid comprising a sense strand and an antisense strand, wherein the sense strand contains 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%) of the sequence shown in any one of SEQ ID NOs: 1 to 80. , 99%) or more sequence identity, the antisense strand contains a sequence having 80% (e.g.
  • the antisense strand has 15 to 30 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) nucleotides (bases).
  • the sense strand has 15 to 30 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) nucleotides (bases).
  • RNA nucleic acid
  • the nucleic acid is selected from at least one of siRNA-1 whose sense chain sequence is SEQ ID NO: 1 and whose antisense chain sequence is SEQ ID NO: 81, siRNA-2 whose sense chain sequence is SEQ ID NO: 2 and whose antisense chain sequence is SEQ ID NO: 82, siRNA-3 whose sense chain sequence is SEQ ID NO: 3 and whose antisense chain sequence is SEQ ID NO: 83, siRNA-4 whose sense chain sequence is SEQ ID NO: 4 and whose antisense chain sequence is SEQ ID NO: 84, siRNA-5 whose sense chain sequence is SEQ ID NO: 5 and whose antisense chain sequence is SEQ ID NO: 85..., siRNA-78, siRNA-79, and siRNA-80.
  • the antisense strand contains at least 15, 16, 17, 18, 19, 20, 21, 22 or 23 consecutive nucleotides that differ from the sequence shown in any one of SEQ ID NOs: 81 to 160 by no more than 0, 1, 2 or 3 nucleotides
  • the positive strand contains a nucleotide sequence that is at least partially complementary (such as partially complementary, substantially complementary or completely complementary) to the antisense strand.
  • the positive strand contains at least 15, 16, 17, 18, 19, 20, 21, 22 or 23 consecutive nucleotides that differ from the sequence shown in any one of SEQ ID NOs: 1 to 80 by no more than 0, 1, 2 or 3 nucleotides.
  • the sense strand and the antisense strand may have the same length or different lengths.
  • nucleotide groups in the above nucleic acid may be chemically unmodified, or may contain at least one modified nucleotide group, and the modification may be on the nucleotide at any position.
  • the sense and antisense strands may be partially complementary, substantially complementary, or fully complementary to each other.
  • the antisense strand contains a nucleotide sequence that differs from any one of SEQ ID NOs: 89, 100, 106, 109, 135, 136, 149, 150, 152, 153, 154, 156, 157, 158, 159, 160 by 0, 1 or 2 nucleotides, and the forward strand contains a nucleotide sequence that is at least partially complementary to the antisense strand.
  • SEQ ID NOs: 89, 100, 106, 109, 135, 136, 149, 150, 152, 153, 154, 156, 157, 158, 159, 160 by 0, 1 or 2 nucleotides
  • the forward strand contains a nucleotide sequence that is at least partially complementary to the antisense strand.
  • the positive strand contains a nucleotide sequence that differs by 0, 1 or 2 nucleotides from the sequence shown in any one of SEQ ID NO: 9, 20, 26, 29, 55, 56, 69, 70, 72, 73, 74, 76, 77, 78, 79, 80.
  • the antisense strand contains a nucleotide sequence that differs by 0, 1 or 2 nucleotides from the sequence shown in any one of SEQ ID NOs: 109, 135, 136, 149, 150, 152, 153, 154, 156, 157, 158, and 159, and the sense strand contains a nucleotide sequence that is at least partially complementary to the antisense strand.
  • the antisense strand has this sequence, the inhibitory effect of the double-stranded RNA with different modifications on HSD17B13 is further improved.
  • the positive strand contains a nucleotide sequence that differs by 0, 1 or 2 nucleotides from the sequence shown in any one of SEQ ID NOs: 29, 55, 56, 69, 70, 72, 73, 74, 76, 77, 78, and 79.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 109 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 29 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 135 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 55 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 136 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 56 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 149 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 69 by 0, 1 or 2 nucleotides.
  • the antisense strand contains the sequence shown in SEQ ID NO: 150
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 70 by 0, 1 or 2 nucleotides.
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 70 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 152 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 72 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 153 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 73 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 154 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 74 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 156 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 76 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 157 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 77 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 158 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 78 by 0, 1 or 2 nucleotides.
  • the antisense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 159 by 0, 1 or 2 nucleotides
  • the sense strand contains a nucleotide sequence that differs from the sequence shown in SEQ ID NO: 79 by 0, 1 or 2 nucleotides.
  • the sequence identity of the sense strand or antisense strand in the nucleic acid with the corresponding sequence mentioned in the present invention is less than 100% or differs by more than 1 nucleotide, it still has the same identity as the corresponding sequence mentioned in the present invention.
  • the inhibitory effect of the corresponding sequence on HSD17B13 is similar or equivalent.
  • the UU connected to the 3' end of the antisense strand of the nucleic acid is replaced by AA, CC, GG or UG, etc., or a combination of any two nucleic acids.
  • Such nucleic acid sequences also belong to the protection scope of the present invention.
  • the nucleic acid contains a nucleotide group as a basic structural unit, and the nucleotide group contains a phosphate group, a ribose group and a base.
  • the nucleic acid contains at least one modified nucleotide group.
  • the inhibition efficiency of the modified nucleic acid on HSD17B13 is not less than 50% (such as 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%).
  • the modified nucleotide group is a nucleotide group in which a phosphate group and/or a ribose group is modified.
  • the modified site can be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 of the 1st, 2nd, 3rd, 4th, 5th, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30th nucleotide of the sense strand and/or the antisense strand.
  • modification of the phosphate group refers to modification of the oxygen in the phosphate group, including phosphorothioate modification and boranophosphate modification.
  • the oxygen in the phosphate group is replaced by sulfur, borane, amine, alkyl or alkoxy.
  • BASE represents the base A, U, C, G or T.
  • X can be oxygen (O) or sulfur (S).
  • R in the above structure can be the same or different, such as: hydrogen (H), fluorine (F), methoxy (OME) or methoxyethyl (MOE), hydroxyl, allyl, ethylamino, propargyl, amino, cyanoethyl, acetyl, etc.
  • R' and R" can each independently be hydrogen (H), methyl (CH3), ethyl (CH2CH3), propyl (CH2CH2CH3), isopropyl (CH(CH3)2), allyl, propargyl, acyloxybenzyl, acyloxyethyl.
  • the modification of the ribose group refers to the modification of the 2′-hydroxyl (2′-OH) in the ribose group.
  • the modification of the 2′-hydroxyl in the pentose of nucleotides includes 2′-fluoro modification (2′-fluoromodification, such as 2′-arabino-fluoro modification), 2′-methoxy modification (2′-OME), 2′-methoxyethyl modification (2′-MOE), 2′-2,4-dinitrophenol modification (2′-DNP modification), cyclolocked ethyl modification (2′,4′-constrained ethyl modification), 2'-Amino modification, 2'-deoxy modification, BNA, acyclic nucleic acid modification, misplaced nucleic acid modification, L-type nucleic acid modification, etc.
  • 2′-fluoromodification such as 2′-arabino-fluoro modification
  • 2′-OME 2′-methoxyethyl modification
  • 2′-MOE 2′-2,4-dinitrophenol modification
  • cyclolocked ethyl modification (2′,4′-constrained e
  • BNA endocyclic bridged nucleotide refers to a constrained or inaccessible nucleotide.
  • BNA can contain a five-membered ring, a six-membered ring, or a seven-membered ring with a "fixed" C 3'-endo sugar condensed bridge structure.
  • the bridge is usually incorporated into the 2'-, 4'-position of the ribose ring to provide a 2', 4'-BNA nucleotide, such as locked ethyl modification (LNA), ring locked ethyl modification (ENA) and ethyl locked nucleic acid modification (cET BNA).
  • LNA locked ethyl modification
  • ENA ring locked ethyl modification
  • cET BNA ethyl locked nucleic acid modification
  • Acyclic nucleic acids are nucleotides formed by opening the sugar ring of the nucleotide, such as unlocked nucleic acid (UNA) nucleotides and glycerol nucleic acid (GNA) nucleotides.
  • Unlocked nucleic acid (UNA) nucleotides and glycerol nucleic acid (GNA) nucleotides are nucleotides formed by opening the sugar ring of the nucleotide, such as unlocked nucleic acid (UNA) nucleotides and glycerol nucleic acid (GNA) nucleotides.
  • Misplaced nucleic acid modification refers to the replacement of the 3', 5'-phosphate bond link by a 2', 5'-phosphate bond chain.
  • L-type nucleic acid modification refers to the replacement of the naturally occurring D-type nucleic acid with its mirror stereo equivalent L-type nucleic acid.
  • BASE represents the base A, U, C, G or T.
  • R in the above structure can be the same or different, such as: hydrogen (H), fluorine (F), methoxy (OME) or methoxyethyl (MOE), hydroxyl, allyl, ethylamino, propargyl, cyanoethyl, acetyl, etc.
  • the nucleotide group in which the ribose group is modified is a nucleotide group in which the 2'-OH of the ribose group is substituted by a methoxy group or a fluorine group.
  • the nucleotide group containing uracil base or cytosine base in the sense strand of the nucleic acid is a nucleotide group in which the ribose group is modified, that is, the nucleotide group containing uracil base or cytosine base in the sense strand of the nucleic acid
  • the 2'-OH of the ribose group in the nucleic acid is replaced by a methoxy group or a fluorine group.
  • the 3' end of the sense strand and the antisense strand of the nucleic acid can be connected to dTdT; or, the 3' end of the antisense strand of the nucleic acid can be connected to AA or UU or a combination of any two nucleic acids (which can be but is not limited to CC, GG or UG), so that the sequence has a specific inducement to mRNA degradation.
  • the nucleic acid with the above modifications shows a more excellent in vivo inhibitory effect, and the above modifications can further reduce the immunogenicity of the nucleic acid of the present invention in vivo.
  • the nucleic acid of the present invention may also include a modification of a monophosphate nucleoside connected to the 5' end of the antisense strand. Since the 5'-monophosphate at the terminal of the siRNA guide strand is important for RISC recognition. Among them, the phosphorylation of the 5'-hydroxyl group plays a certain role in whether the siRNA can be effectively loaded into the Ago2 inside the cell.
  • the 5'-terminal monophosphate of the guide strand in the siRNA has an H bond interaction with Argonaute-2 (Ago2), thereby ensuring accurate positioning and precise cutting of the mRNA target.
  • Ago2 Argonaute-2
  • phosphate nucleoside derivatives have been proven to have certain stability in biological metabolic media and have a certain effect on promoting the loading of siRNA guide strands into Ago2 inside cells (Nucleic Acids Research, 2015, 43, 2993-3011).
  • trans-vinyl phosphate (VP) is the first choice
  • monophosphate nucleoside derivatives other than those described above may also be included.
  • BASE represents the base A, U, C, G or T.
  • R in the above structure can be The radicals may be the same or different, such as hydrogen (H), fluorine (F), methoxy (OME) or methoxyethyl (MOE), hydroxyl, allyl, ethylamino, propargyl, cyanoethyl, amino, acetyl, etc.
  • At least one nucleotide in the nucleic acid is a modified nucleotide or includes a modified linkage.
  • the modified nucleotide is selected from one or more of 2'-O-methyl nucleotides, 2'-fluoro nucleotides, 2'-deoxy nucleotides, 2',3'-open ring nucleotide mimics, locked nucleotides, 2'-F-arabino nucleotides, 2'-methoxyethyl nucleotides, abasic nucleotides, ribitols, reverse nucleotides, reverse 2'-O-methyl nucleotides, reverse 2'-deoxy nucleotides, 2'-amino modified nucleotides, 2'-alkyl modified nucleotides, morpholino nucleotides, nucleotides containing vinyl phosphonate, nucleotides containing cyclopropyl phosphonate and 3'-O-methyl nucleotides; the modified nucleotide is further preferably selected from one or more of 2'-O-methyl
  • the modified inter-linkage is preferably selected from one or more of phosphorothioate inter-nucleotide linkages and methylphosphonate inter-nucleotide linkages; the modified inter-linkage is further preferably selected from one or more of phosphorothioate monoester inter-nucleotide linkages and phosphorothioate diester inter-nucleotide linkages.
  • the antisense strand contains two phosphorothioate internucleotide bonds at the 5' end and the 3' end, respectively, and contains 4 to 6 2'-fluoro nucleotides, and the remaining nucleotides are 2'-O-methyl nucleotides.
  • the 5' end of the sense strand contains two phosphorothioate internucleotide bonds and 2 to 4 2'-fluoro nucleotides, and the remaining nucleotides are all 2'-O-methyl nucleotides.
  • the antisense strand has 2'-fluoro nucleotides at the 2nd, 4th, 6th, 14th and 16th nucleotides counted from the 5' end.
  • the sense strand has 2'-fluoro nucleotides at the 7th, 9th and 11th nucleotides counted from the 5' end.
  • the antisense strand has at least 15, 16, 17, 18, 19, 20, 21, 22 or 23 consecutive nucleotides that differ from the antisense strand sequence of any one of Table 2 by no more than 0, 1, 2 or 3 nucleotides
  • the sense strand has at least 15, 16, 17, 18, 19, 20, 21, 22 or 23 consecutive nucleotides that differ from the sense strand sequence of any one of Table 2 by no more than 0, 1, 2 or 3 nucleotides.
  • the sense strand and the antisense strand form a siRNA having any one of the sequences shown in Table 3.
  • the antisense strand contains a nucleotide sequence from the 5' end to the 3' end that differs from the following nucleotide sequence by 0, 1 or 2 nucleotides:
  • the sense strand contains a nucleotide sequence that is at least partially complementary to the antisense strand.
  • the sense strand contains a nucleotide sequence from the 5' end to the 3' end that differs by 0, 1 or 2 nucleotides from any of the following nucleotide sequences:
  • SN-22401 gsusuuuuuCfaCfaUfguauuauaga.
  • a nucleotide represented by a lowercase letter represents that the nucleotide is 2'-O- Methyl nucleotide; f means that the adjacent nucleotide on its left is a 2'-fluoro nucleotide; s means that the two adjacent nucleotides on the left and right are connected by a phosphorothioate diester bond.
  • the antisense strand contains a nucleotide sequence from the 5' end to the 3' end that differs from the following nucleotide sequence by 0, 1 or 2 nucleotides:
  • the sense strand contains a nucleotide sequence that is at least partially complementary to the antisense strand.
  • the sense strand contains a nucleotide sequence from the 5' end to the 3' end that differs by 0, 1 or 2 nucleotides from any of the following nucleotide sequences:
  • SN-22400 gsusguuuUfuCfaCfauguauuaua.
  • those skilled in the art can combine the sense and antisense strand sequences mentioned above in consideration of the complementarity of the sense and antisense strands.
  • the sense and antisense strand sequences with the same last three digits are combined to obtain the corresponding nucleic acid (siRNA).
  • SN-5577 and SN-2577 are combined, and SN-52389 and SN-22389 are combined to obtain the corresponding nucleic acid (siRNA).
  • the nucleic acid according to the present invention can be obtained by conventional methods in the art, such as solid phase synthesis and liquid phase synthesis, and the solid phase synthesis has commercial custom services and can therefore be obtained commercially.
  • the modified nucleotide group can be introduced by a nucleotide monomer having a corresponding modification.
  • the present invention can further construct an shRNA expression plasmid having the same or similar function as the above siRNA.
  • the method for constructing the expression plasmid is well known to those skilled in the art and will not be described in detail here.
  • the present invention also provides a targeted gene site of the nucleic acid as described above.
  • the targeted gene site is annotated as any one of the items in column 1 of Table 1.
  • the first column refers to the position of the first base of the targeted gene in the HSD17B13 gene sequence, and so on; the numbers in the third and fifth columns represent the sequence numbers, for example, "1" represents SEQ ID NO: 1.
  • the reference sequence of the targeted gene is the coding sequence of human HSD17B13 NM_178135.5
  • the present invention also provides a targeted drug delivery system, characterized in that the targeted drug delivery system comprises a targeting group, a linking group and the above-mentioned of nucleic acid.
  • the nucleic acid (siRNA) of the present invention has a better inhibitory effect when applied to different targeted drug delivery systems.
  • the effect advantage of the naked sequence and the modified sequence in the present invention does not depend on the selection of the targeting carrier.
  • the present invention also optimizes the targeted drug delivery system and obtains the following technical scheme.
  • the linker is linked to the 3' end or the 5' end of the sense strand or the antisense strand of the nucleic acid.
  • the linker is attached to the 3' end of the sense strand of the nucleic acid.
  • the targeted drug delivery system comprises a ligand and the nucleic acid linked to the ligand.
  • the ligand is a GalNAc derivative.
  • the ligand is one or more GalNAc derivatives connected by single-stranded, double-stranded, or triple-stranded branched linkers.
  • the structure of the targeted drug delivery system is shown in Formula I below:
  • Nu represents the nucleic acid (siRNA).
  • the compound part in the system can be connected to the 5' end or 3' end of the sense strand of the siRNA through a phosphodiester bond, and can also be connected to the 5' end or 3' end of the antisense strand of the siRNA through a phosphodiester bond.
  • the targeted drug delivery system utilizes the structural characteristics on its left side to improve the cell penetration ability of the nucleic acid drug (Nu), enhance its stability in the cell, and has a simple preparation process and strong practicality.
  • the present invention also provides a pharmaceutical composition, which contains the nucleic acid or targeted drug delivery system as described above and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can be prepared from the nucleic acid and the pharmaceutically acceptable carrier by conventional methods.
  • the pharmaceutical composition can be an injection.
  • the injection can be used for subcutaneous, intramuscular or intravenous injection.
  • the content of the pharmaceutically acceptable carrier can be 1-100000 parts by weight (such as 1 part by weight, 5 parts by weight, 10 parts by weight, 50 parts by weight, 100 parts by weight, 500 parts by weight, 1000 parts by weight, 5000 parts by weight, 10000 parts by weight, 50000 parts by weight, 100000 parts by weight or any value between any two of the above values).
  • the pharmaceutically acceptable carrier may be various carriers conventionally used in the art, for example, it may include at least one of a pH buffer, a protective agent and an osmotic pressure regulator.
  • the pH buffer may be a tris(hydroxymethyl)aminomethane hydrochloride buffer with a pH of 7.5-8.5 and/or a phosphate buffer with a pH of 5.5-8.5, preferably a phosphate buffer with a pH of 5.5-8.5.
  • the protective agent may be at least one of inositol, sorbitol and sucrose.
  • the content of the protective agent may be 0.01-30% by weight (such as 0.01% by weight, 0.05% by weight, 0.1% by weight, 0.5% by weight, 1% by weight, 5% by weight, 10% by weight, 15% by weight, 20% by weight, 25% by weight, 30% by weight).
  • the osmotic pressure regulator may be sodium chloride and/or potassium chloride.
  • the content of the osmotic pressure regulator makes the osmotic pressure of the pharmaceutical composition 200-700 mOsmole/kg. According to the desired osmotic pressure, those skilled in the art can determine the content of the osmotic pressure regulator.
  • the pharmaceutically acceptable carrier is a liposome.
  • the liposome can be any liposome capable of encapsulating nucleic acid, and its diameter can be 25-1000 nm, and can include but not limited to cholesterol and its analogs or derivatives.
  • the dosage of the pharmaceutical composition of the present invention can be a conventional dosage in the art, and the dosage can be determined according to various parameters, especially according to the age, weight and gender of the subject. For example, for female, 3-4 month old mice weighing 25-30 g, based on the amount of the nucleic acid in the pharmaceutical composition, the dosage of the pharmaceutical composition can be 0.01-100 mg/kg body weight, preferably 1-10 mg/kg body weight.
  • the present invention also provides a method for inhibiting the expression of 17- ⁇ -hydroxysteroid dehydrogenase 13 gene in a cell, the method comprising: contacting the cell with the nucleic acid, targeted drug delivery system or pharmaceutical composition as described above to inhibit the expression of 17- ⁇ -hydroxysteroid dehydrogenase 13 gene in the cell.
  • the cell is in a subject, e.g., a human subject, e.g., a subject suffering from a 17- ⁇ -hydroxysteroid dehydrogenase 13-associated disease.
  • the cell is in vitro.
  • the method is for research purposes or for constructing an animal model.
  • contacting the cell with the nucleic acid inhibits expression of HSD17B13 by at least 50%, 60%, 70%, 80%, 90%, 95% (e.g., compared to the expression level of HSD17B13 before the cell was first contacted with the nucleic acid; e.g., before the first dose of the nucleic acid was administered to the subject).
  • inhibiting expression of HSD17B13 reduces the level of HSD17B13 protein in a serum sample of the subject by at least 50%, 60%, 70%, 80%, 90%, 95%. 80%, 90% or 95%, for example, compared to the expression level of HSD17B13 before the cell is first contacted with the nucleic acid.
  • the present invention also provides the use of the nucleic acid as described above, the targeted drug delivery system as described above, or the pharmaceutical composition as described above in any of the following aspects: 1) treating and/or preventing diseases associated with 17- ⁇ -hydroxysteroid dehydrogenase 13; 2) preparing drugs for treating and/or preventing diseases associated with 17- ⁇ -hydroxysteroid dehydrogenase 13.
  • the disease is: (i) a disease associated with increased or elevated levels of 17- ⁇ -hydroxysteroid dehydrogenase 13; or (ii) a disease that would benefit from decreased expression of 17- ⁇ -hydroxysteroid dehydrogenase 13.
  • the disease is selected from one or more of the following: non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, alcoholic steatohepatitis (ASH), alcoholic fatty liver disease (ALD), cirrhosis, hepatitis, hepatitis C virus (HCV)-related cirrhosis, drug-induced liver injury, and hepatocellular necrosis.
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • ASH alcoholic steatohepatitis
  • ALD alcoholic fatty liver disease
  • cirrhosis hepatitis
  • HCV hepatitis C virus
  • the subject may be a mammal, including primates (such as humans, non-human primates, such as monkeys and chimpanzees), non-primates (such as cattle, pigs, horses, goats, rabbits, sheep, hamsters, guinea pigs, cats, dogs, rats or mice) or birds.
  • the subject is preferably a primate, more preferably a human.
  • Administration can be by a variety of routes, depending on whether local or systemic treatment is required.
  • the mode of administration can be, but is not limited to, intravenous administration, intra-arterial administration, subcutaneous administration, intraperitoneal administration, transdermal administration (such as by implantation of a device) and administration into soft tissue.
  • the dosage can refer to the above, and will not be repeated here.
  • the nucleic acid, the targeted drug delivery system or the pharmaceutical composition is administered to the subject by subcutaneous administration, intravenous administration and/or intramuscular administration.
  • the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified.
  • acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
  • each sense strand and antisense strand was modified, and the modified sequences are shown in Table 2.
  • a/c/g/u 2'-OMe nucleotides
  • Af/Cf/Gf/Uf 2'-F nucleotides
  • s phosphorothioate diester bond.
  • the sense strand and antisense strand in Table 2 were synthesized into the modified double-stranded siRNA in Table 3 by solid phase synthesis.
  • a/c/g/u 2'-OMe nucleotides
  • Af/Cf/Gf/Uf 2'-F nucleotides
  • s phosphorothioate diester bond.
  • the specific process of the experiment is as follows: 50 microliters of cell culture medium (DMEM, 10% calf serum) containing 25,000 HEK293T cells were added to the 96-well cell culture dish coated with gelatin, and siRNA transfection was performed after incubation overnight. 20X sample working solution was prepared in Opti-MEM, and plasmids containing human HSD17B13 gene and luciferase-renilla fragment were prepared in Opti-MEM to make the final concentration of plasmid 5ng/mL. 0.5mL Lipofectamine was added to 24.5mL Opti-MEM.
  • siRNA compounds human and monkey homologous siRNA (Table 5) was screened in the above HEK293T cell system at 8 doses (0.001, 0.011, 0.033, 0.06, 0.11, 0.33, 1.1, 3.3 nM).
  • a/c/g/u 2'-OMe nucleotides
  • Af/Cf/Gf/Uf 2'-F nucleotides
  • s phosphorothioate diester bond.
  • a/c/g/u 2'-OMe nucleotides
  • Af/Cf/Gf/Uf 2'-F nucleotides
  • s phosphorothioate diester bond.
  • siRNA drugs shown in Table 7 were tested for efficacy in human HSD17B13 transgenic mice, they still had significant efficacy advantages.
  • the siRNA drugs of the present invention can achieve better efficacy at a lower dose.
  • siRNA of the present invention has obvious effect advantages at the naked sequence level, and its effect in silencing the HSD17B13 gene is significantly better than the existing advantageous sequences.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte au domaine technique de la biologie, et concerne un acide nucléique ciblant l'hydroxystéroïde 17-β déshydrogénase 13 et son utilisation. L'acide nucléique selon l'invention peut inhiber efficacement l'expression de l'hydroxystéroïde 17-β déshydrogénase 13, et peut ainsi traiter et/ou prévenir des maladies associées à l'activation de l'hydroxystéroïde 17-β déshydrogénase 13.
PCT/CN2024/098565 2023-06-16 2024-06-12 ACIDE NUCLÉIQUE CIBLANT L'HYDROXYSTÉROÏDE 17-β DÉSHYDROGÉNASE 13 ET SON UTILISATION Pending WO2024255748A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310718422.1 2023-06-16
CN202310718422 2023-06-16

Publications (1)

Publication Number Publication Date
WO2024255748A1 true WO2024255748A1 (fr) 2024-12-19

Family

ID=92991008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2024/098565 Pending WO2024255748A1 (fr) 2023-06-16 2024-06-12 ACIDE NUCLÉIQUE CIBLANT L'HYDROXYSTÉROÏDE 17-β DÉSHYDROGÉNASE 13 ET SON UTILISATION

Country Status (2)

Country Link
CN (1) CN118773194A (fr)
WO (1) WO2024255748A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020556A (zh) * 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法
US20210000906A1 (en) * 2018-03-21 2021-01-07 Ionis Pharmaceuticals, Inc. Modulation of hsd17b13 expression
CN113164509A (zh) * 2018-09-19 2021-07-23 箭头药业股份有限公司 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
WO2021211959A2 (fr) * 2020-04-18 2021-10-21 Inipharm, Inc. Procédés et compositions pour le traitement de la stéatohépatite induite par un médicament
WO2021247885A2 (fr) * 2020-06-01 2021-12-09 Amgen Inc. Constructions d'arni pour l'inhibition de l'expression de hsd17b13 et procédés d'utilisation de celles-ci
WO2022223015A1 (fr) * 2021-04-22 2022-10-27 上海拓界生物医药科技有限公司 Arnsi ciblant la 17β-hydroxystéroïde déshydrogénase de type 13 et conjugué d'arnsi
WO2023039076A1 (fr) * 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Molécules d'acide nucléique interférent court modifiées (sina) et leurs utilisations
WO2023091644A2 (fr) * 2021-11-19 2023-05-25 Wave Life Sciences Ltd. Compositions oligonuclétiques double brin associées à hsd17b13 et procédés s'y rapportant

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020556A (zh) * 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法
US20210000906A1 (en) * 2018-03-21 2021-01-07 Ionis Pharmaceuticals, Inc. Modulation of hsd17b13 expression
CN113164509A (zh) * 2018-09-19 2021-07-23 箭头药业股份有限公司 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
WO2021211959A2 (fr) * 2020-04-18 2021-10-21 Inipharm, Inc. Procédés et compositions pour le traitement de la stéatohépatite induite par un médicament
WO2021247885A2 (fr) * 2020-06-01 2021-12-09 Amgen Inc. Constructions d'arni pour l'inhibition de l'expression de hsd17b13 et procédés d'utilisation de celles-ci
CN116234907A (zh) * 2020-06-01 2023-06-06 美国安进公司 用于抑制hsd17b13表达的rnai构建体及其使用方法
WO2022223015A1 (fr) * 2021-04-22 2022-10-27 上海拓界生物医药科技有限公司 Arnsi ciblant la 17β-hydroxystéroïde déshydrogénase de type 13 et conjugué d'arnsi
WO2023039076A1 (fr) * 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Molécules d'acide nucléique interférent court modifiées (sina) et leurs utilisations
WO2023091644A2 (fr) * 2021-11-19 2023-05-25 Wave Life Sciences Ltd. Compositions oligonuclétiques double brin associées à hsd17b13 et procédés s'y rapportant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LUUKKONEN PANU K., IKKI SAKUMA, RAFAEL C GASPAR, MEGHAN MOORING, ALI NASIRI, MARIO KAHN, XIAN-MAN ZHANG, DONGYAN ZHANG, HENNA SAMM: "Inhibition of HSD17B13 Protects against Liver Fibrosis by Inhibition of Pyrimidine Catabolism in Nonalcoholic Steatohepatitis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 120, no. 4, pages e2217543120, XP093247805 *
MA YANLING, KARKI SUMAN, BROWN PHILIP M., LIN DENNIS D., PODSZUN MAREN C., ZHOU WENCHANG, BELYAEVA OLGA V., KEDISHVILI NATALIA Y.,: "Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity", JOURNAL OF LIPID RESEARCH, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC., US, vol. 61, no. 11, 1 November 2020 (2020-11-01), US , pages 1400 - 1409, XP093247794, ISSN: 0022-2275, DOI: 10.1194/jlr.RA120000907 *
WANG MEIXI, LI JIANRUI, LI HU, DONG BIAO, JIANG JING, LIU NANNAN, TAN JIALI, WANG XUEKAI, LEI LEI, LI HONGYING, SUN HAN, TANG MEI,: "Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (MDPI), BASEL, CH, vol. 23, no. 10, Basel, CH , pages 5544, XP093247797, ISSN: 1422-0067, DOI: 10.3390/ijms23105544 *

Also Published As

Publication number Publication date
CN118773194A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
US11655473B2 (en) Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression
CN111971051A (zh) 用增加tm的核苷酸修饰的双链核酸抑制剂分子
CN121294438A (zh) 高级rna靶向(arnatar)
JP2022530678A (ja) 短縮センス鎖を有する二本鎖核酸阻害剤分子
WO2025002247A1 (fr) Acide nucléique ciblant la protéine 3 de type angiopoïétine humaine et son utilisation
WO2025201416A1 (fr) ACIDE NUCLÉIQUE CIBLANT LA SOUS-UNITÉ βE DE L'INHIBINE ET UTILISATION ASSOCIÉE
WO2024255748A1 (fr) ACIDE NUCLÉIQUE CIBLANT L'HYDROXYSTÉROÏDE 17-β DÉSHYDROGÉNASE 13 ET SON UTILISATION
CA3235941A1 (fr) Compositions et procedes de modulation de l'expression d'apoc3
WO2024260379A1 (fr) Acide nucléique ciblant la cétohexokinase et son utilisation
WO2024260380A1 (fr) Acide nucléique ciblant la lipoprotéine a et son utilisation
WO2024255747A1 (fr) Acide nucléique ciblant le composant 5 du complément et son utilisation
JP7216381B2 (ja) Ｒｎａ作用抑制剤及びその利用
WO2024255749A1 (fr) Acide nucléique ciblant l'angiotensinogène et son utilisation
WO2026037221A1 (fr) Réactif d'arni ciblant le complément c3 et son utilisation
WO2025061204A1 (fr) Composé pour maladies associées au vhb et son utilisation
WO2025201156A1 (fr) Acide nucléique ciblant le facteur xi de coagulation et utilisation associée
WO2025153088A1 (fr) OLIGONUCLÉOTIDE CIBLANT LA 17β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 13 ET SON UTILISATION
HK40116803A (zh) 靶向血管紧张素原的核酸及其用途
WO2026026937A1 (fr) Arnsi pour inhiber l'expression du gène hsd17b13 et modification et utilisation associées
WO2024229229A2 (fr) Produits et compositions
WO2024164001A2 (fr) Produits et compositions
WO2024254589A9 (fr) Produits et compositions
CN119013402A (zh) 调节scap活性的组合物和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24822697

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE